8-K: Haemonetics Q3 FY26 Results: Guidance Raised on Strong Core

Haemonetics Corporation reported strong third-quarter and year-to-date fiscal 2026 financial results, leading to an upward revision of its full-year guidance.

Summary

• Third quarter fiscal 2026 revenue was $339.0 million, a 2.7% decrease compared to the prior year, but organic revenue increased by 1.2%, and organic ex-CSL revenue increased by 7.5%.
• Year-to-date fiscal 2026 revenue was $988 million, a 4.1% decrease, with organic ex-CSL revenue increasing by 9.8%.
• GAAP earnings per diluted share for Q3 FY26 were $0.95, up 28.4% from $0.74 in Q3 FY25.
• Adjusted earnings per diluted share for Q3 FY26 were $1.31, up 10.1% from $1.19 in Q3 FY25.
• Cash flow from operating activities for Q3 FY26 was $93.6 million, an increase of 113.8% compared to the prior year.
• Free cash flow for Q3 FY26 was $74.2 million, an increase of 150.9% compared to the prior year.
• The company raised its fiscal 2026 guidance for total company organic ex-CSL revenue growth to 8-10% (previously 7-10%).
• Adjusted earnings per diluted share guidance for fiscal 2026 was raised to $4.90-$5.00 (previously $4.80-$5.00).
• Free cash flow guidance for fiscal 2026 was raised to $200 million-$220 million (previously $170 million-$210 million).

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, driven by robust core business performance, significant cash flow generation, and an upward revision of full-year financial guidance, despite some revenue declines in specific segments.

Positives

• Strong underlying performance in core businesses, particularly Blood Management Technologies and Plasma, driving revenue growth, margin expansion, and cash flow.
• GAAP earnings per diluted share increased by 28.4% to $0.95 in Q3 FY26 and 15.0% to $2.46 year-to-date FY26.
• Adjusted earnings per diluted share increased by 10.1% to $1.31 in Q3 FY26.
• Cash flow from operating activities significantly increased by 113.8% to $93.6 million in Q3 FY26.
• Free cash flow substantially increased by 150.9% to $74.2 million in Q3 FY26.
• Gross margin expanded to 59.7% (GAAP) and 60.2% (Adjusted) in Q3 FY26, driven by portfolio transformation to higher-margin offerings and product innovation.
• Raised fiscal 2026 guidance for adjusted earnings per diluted share and free cash flow, indicating increased confidence in future performance.
• Plasma business unit showed strong organic ex-CSL revenue growth of 20.2% in Q3 FY26 and 22.1% year-to-date FY26.
• Blood Management Technologies within the Hospital business unit achieved 7.6% organic growth in Q3 FY26 and 11.1% year-to-date FY26.

Negatives

• Reported total net revenue decreased by 2.7% in Q3 FY26 and 4.1% year-to-date FY26.
• Blood Center reported revenue decreased by 19.6% in Q3 FY26 and year-to-date FY26, primarily due to the divestiture of the Whole Blood product line and exit of certain liquid solution products.
• Interventional Technologies reported revenue decreased by 11.4% in Q3 FY26 and 7.8% year-to-date FY26, requiring targeted actions to reestablish momentum.
• Hospital reported revenue decreased by 0.3% in Q3 FY26.
• Operating expenses increased by 0.4% in Q3 FY26, driven by higher performance-based compensation.
• Interest and other expense, net, increased by 155.0% year-to-date FY26 to $(23,330) thousand.

Risks

• Availability and demand for the company's products.
• Ability to successfully develop and market new products and technologies.
• Impact of competitive products and pricing.
• Product quality issues.
• Disruptions caused by cybersecurity events.
• Failure to realize anticipated strategic benefits and opportunities from acquisitions and divestitures.
• Pricing pressures resulting from trends toward healthcare cost containment and the effect of industry consolidation.
• Manufacturing, distribution, and supply chain disruptions and cost increases.
• Ability to implement as planned and realize estimated cost savings from the market and regional alignment initiative.
• Effects of global economic and political conditions, including changing trade and tariff policies and inflationary pressures.
• Regulatory uncertainties, including in the receipt or timing of regulatory approvals, and the impact of changes in global regulatory conditions.
• Indebtedness incurred by the company, including the conditional conversion feature of its convertible notes.
• Ability to protect its intellectual property.
• Litigation.
• Impact of share repurchases on the company's stock price and volatility as well as the effect of short-term price fluctuations on the share repurchase programs effectiveness.

Future Outlook

Haemonetics raised its fiscal 2026 guidance for total company organic ex-CSL revenue growth to 8-10%, adjusted earnings per diluted share to $4.90-$5.00, and free cash flow to $200 million-$220 million, reflecting confidence in its core businesses and upcoming product launches, including PerQseal Elite in the US.

Management Comments

• "Third quarter revenue growth, margin expansion, and cash flow reflect the underlying strength of our core businesses."
• "Blood Management Technologies and Plasma continue to drive our strong performance while we take targeted actions to reestablish momentum in Interventional Technologies and prepare for a US launch of PerQseal Elite."
• "We are well positioned to finish the fiscal year strong and deliver our long-term growth and value creation objectives throughout our business."

Industry Context

StockSavvy.ai notes that Haemonetics' focus on high-margin offerings and product innovation aligns with broader trends in the medical technology sector, where companies are increasingly seeking to optimize portfolios for profitability and address specific, high-value medical needs. The strong performance in Plasma and Blood Management Technologies suggests resilience in critical healthcare segments, while challenges in Interventional Technologies highlight the competitive and dynamic nature of specialized medical device markets.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks.

Stakeholder Impact

• Shareholders: Positive impact due to increased earnings, cash flow, and raised guidance, potentially leading to increased share value.
• Employees: Higher performance-based compensation suggests a positive impact for some employees.
• Customers: Benefits from product innovation and higher margin offerings, potentially leading to improved product quality and effectiveness.
• Creditors: Improved cash flow and financial health could enhance the company's creditworthiness.

Next Steps

• Take targeted actions to reestablish momentum in Interventional Technologies.
• Prepare for a US launch of PerQseal Elite.
• Host a conference call with investors and analysts on February 5, 2026, at 8:00 a.m. ET to discuss results.
• Deliver long-term growth and value creation objectives throughout the business.

Key Dates

Recommendation

The company demonstrated strong underlying business performance, particularly in its Plasma and Blood Management Technologies segments, leading to significant increases in cash flow and profitability. The upward revision of full-year guidance for adjusted EPS and free cash flow, coupled with gross margin expansion and strategic product launches like PerQseal Elite, indicates a positive trajectory and strong operational execution. These factors suggest a compelling investment opportunity.

Keywords

Haemonetics, HAE, medical technology, financial results, Q3 2026, earnings, plasma, blood management, hospital technologies, interventional technologies, organic revenue, adjusted EPS, free cash flow, guidance